Meadowbrook Advisors Group LLC Acquires New Position in Astrazeneca Plc $AZN

Meadowbrook Advisors Group LLC acquired a new stake in shares of Astrazeneca Plc (NYSE:AZN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,695 shares of the company’s stock, valued at approximately $648,000.

A number of other large investors also recently bought and sold shares of AZN. Triumph Capital Management bought a new stake in shares of Astrazeneca in the 3rd quarter valued at approximately $25,000. MV Capital Management Inc. acquired a new stake in shares of Astrazeneca during the 4th quarter valued at approximately $26,000. Bangor Savings Bank lifted its stake in Astrazeneca by 102.7% during the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares during the last quarter. Eagle Bay Advisors LLC bought a new position in Astrazeneca during the fourth quarter worth $30,000. Finally, YANKCOM Partnership acquired a new position in Astrazeneca in the fourth quarter worth $31,000. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Trading Down 0.0%

NYSE:AZN opened at $174.87 on Friday. Astrazeneca Plc has a 12-month low of $137.23 and a 12-month high of $212.71. The firm has a market capitalization of $271.20 billion, a P/E ratio of 26.26, a P/E/G ratio of 1.52 and a beta of 0.25. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The business has a 50 day simple moving average of $186.62 and a 200 day simple moving average of $186.27.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Equities research analysts predict that Astrazeneca Plc will post 9.39 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Barclays reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Finally, Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.